Fasciola hepatica infection: Clinical and radiological findings in pediatric patients

Turkish Journal of Pediatrics

Volumn 54, Issue 4, 2012, Pages 362-367

  Karadaǧ Öncel, Eda ^a   Özsürekçi, Yasemin ^a   Özkaya Parlakay, Aslinur ^a   Çelik, Melda ^a   Cengiz, Ali Bülent ^a   Haliloǧlu, Mithat ^a   Ceyhan, Mehmet ^a   Kara, Ateş ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Child; Clinical and radiological findings; Fasciola hepatica

Indexed keywords

TRICLABENDAZOLE;

ABDOMINAL PAIN; ADOLESCENT; ARTHRALGIA; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; EPIGASTRIC PAIN; FAMILY HISTORY; FASCIOLA HEPATICA; FASCIOLIASIS; FATIGUE; FEMALE; FEVER; HEADACHE; HEPATOGRAPHY; HEPATOSPLENOMEGALY; HUMAN; LABORATORY DIAGNOSIS; MALAISE; MALE; MYALGIA; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE DRUG DOSE; SKIN MANIFESTATION; SUMMER; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION; WINTER;

ADOLESCENT; ANIMALS; ANTHELMINTICS; BENZIMIDAZOLES; CHILD; DIAGNOSTIC IMAGING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FASCIOLA HEPATICA; FASCIOLIASIS; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; RETROSPECTIVE STUDIES; TURKEY;

EID: 84873811625     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Keiser J, Utzinger J. Emerging foodborne trematodiasis. Emerg Infect Dis 2005; 11: 1507-1514.
2. Mas-Coma MS, Esteban JG, Bargues MD. Epidemiology of human fascioliasis: a review and proposed new classification. Bull World Health Organ 1999; 77: 340-346.
3. Marcos LA, Terashima A, Leguia G, et al. Fasciola hepatica infection in Peru: an emergent disease. Rev Gastroenterol Peru 2007; 27: 389-396.
4. Marcos LA, Terashima A. Update on human fascioliasis in Peru: diagnosis, treatment and clinical classification proposal. Neotrop Helminthol 2007; 1: 85-103.
5. Ozturhan H, Emekdaş G, Sezgin O, Korkmaz M, Altintaş E Fasciola hepatica in Mersin province and surrounding towns and the role of family history of the Fascioliasis in the transmission of the parasite. Turk J Gastroenterol 2009; 20: 198-203.
6. Marcos LA, Maco V, Samalvides F, et al. Risk factors for Fasciola hepatica infection in children: a case-control study. Trans R Soc Trop Med Hyg 2006; 100: 158-166.
7. Jensenius M, Flaegstad T, Stenstad T, et al. Fascioliasis imported to Norway. Scand J Infect Dis 2005; 37: 534-537.
8. Marcos LA, Terashima A, Gotuzzo E. Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. Curr Opin Infect Dis 2008; 21: 523-530.
9. Arjona R, Riancho JA, Aguado JM, Salesa R, González-Macías J. Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine (Baltimore) 1995; 74: 13-23.
10. Marcos LA, Maco V, Terashima A, et al. Clinical characteristics of Fasciola hepatica chronic infection in children. Rev Gastroenterol Peru 2002; 22: 228-233.
11. Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin Infect Dis 2001; 33: 1-5.
12. Marcos LA, Maco V, Terashima A, et al. Fascioliasis in relatives of patients with Fasciola hepatica infection in Peru. Rev Inst Med Trop Sao Paulo 2005; 47: 219-222.
13. World Health Organization. Report of the WHO Informal Meeting on use of triclabendazole in fascioliasis control. Geneva: WHO/CDS/NTD/PCT/2007.1: 1-33.
14. Rana SS, Bhasin DK, Nanda M, Singh K. Parasitic infestations of the biliary tract. Curr Gastroenterol Rep 2007; 9: 156-164.
15. Aroonroch R, Worawichawong S, Nitiyanant P, et al. Hepatic fascioliasis due to Fasciola hepatica: a two-case report. J Med Assoc Thai 2006; 89: 1770-1774.
16. Aksoy DY, Kerimoǧlu U, Oto A, et al. Fasciola hepatica infection: clinical and computerized tomographic findings of ten patients. Turk J Gastroenterol 2006; 17: 40-45.
17. Makay O, Gurcu B, Caliskan C, Nart D, Tuncyürek M, Korkut M. Ectopic fascioliasis mimicking a colon tumor. World J Gastroenterol 2007; 13: 2633-2635.
18. El-Karaksy H, Hassanein B, Okasha S, Behairy B, Gadallah I. Human fascioliasis in Egyptian children: successful treatment with triclabendazole. J Tropic Pediatr 1999; 45: 135-138.
19. Mailles A, Capek I, Ajana F, Schepens C, Ilef D, Vaillant V. Commercial watercress as an emerging source of fascioliasis in Northern France in 2002: results from an outbreak investigation. Epidemiol Infect 2006; 134: 942-945.
20. El-Shazly AM, Soliman M, Gabr A, et al. Clinico-epidemiological study of human fascioliasis in an endemic focus in Dakahlia Governorate. J Egypt Soc Parasitol 2001; 31: 725-726.
21. Kiliç E, Tezer H, Kiliç M, et al. Fasciola hepatica, bir parazitik enfestasyonda radyolojik tani: bir vaka takdimi. Çocuk Saǧliǧi ve Hastaliklari Dergisi 2009; 52: 216-218.
22. Cosme A, Ojeda E, Cilla G, et al. Fasciola hepatica study of a series of 37 patients. Gastroenterol Hepatol 2001; 24: 375-380.
23. Marcos LA, Tagle M, Terashima A, et al. Natural history, clinico-radiologic correlates and response to triclabendazole in acute massive fascioliasis. Am J Trop Med Hyg 2008; 78: 222-227.
24. Kabaalioglu A, Cubuk M, Senol U, et al. Fascioliasis: US, CT, and MRI findings with new observations. Abdom Imaging 2000; 25: 400-404.
25. Acosta-Ferreira W, Vercelli-Retta J, Falconi LM. Fasciola hepatica human infection. Histopathological study of sixteen cases. Virchows Arch A Pathol Anat Hist 1979; 383: 319-327.
26. Price TA, Tuazon CU, Simon GL. Fascioliasis: case reports and review. Clin Infect Dis 1993; 17: 426-430.
27. Mas-Coma S, Valero MA, Bargues MD. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv Parasitol 2009; 69: 141-146.
28. Faraq H F, Salem AI, Khalil SS, Farahat A. Studies on human fascioliasis in Egypt. 1--Seasonality of transmission. J Egypt Soc Parasitol 1993; 23: 331-340.
29. Keiser J, Engels D, Buscher G, Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 2005; 14: 1513-1526.
30. Apt W, Aguilera X, Vega F, et al. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg 1995; 52: 532-535.
31. Stitt AW, Fairweather I. The effect of the sulphoxide metabolite of triclabendazole ('Fasinex') on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica. Parasitology 1994; 108: 555-567.
32. Mannstadt M, Sing A, Leitritz L, Brenner-Maucher K, Bogner J. Conservative management of biliary obstruction due to Fasciola hepatica. Clin Infect Dis 2000; 31: 1301-1303.